| Identification | Back Directory | [Name]
AMG 837 (calciuM hydrate) | [CAS]
1259389-38-2 | [Synonyms]
AMG 837 (calciuM hydrate)
AMG-837 CALCIUM HYDRATE;AMG837 CALCIUM HYDRATE | [Molecular Formula]
C26H25CaF3O4 | [MDL Number]
MFCD28167803 | [MOL File]
1259389-38-2.mol | [Molecular Weight]
498.56 |
| Hazard Information | Back Directory | [Uses]
AMG 837 calcium hydrate is a potent, orally bioavailable and partial agonist of GPR40/FFA1. AMG 837 calcium hydrate inhibits specific [3H]AMG 837 binding at the human FFA1 receptor with a pIC50 of 8.13. AMG 837 calcium hydrate could enhance insulin secretion and lower glucose levels in rodents[1][2][3]. AMG 837 (calcium hydrate) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups. | [in vivo]
AMG 837 (0.03-0.3 mg/kg; p.o. once daily for 21 days) reduces glucose levels and increases insulin levels following glucose challenge in vivo[1].
AMG 837 (0.03-0.3 mg/kg; a single p.o.) improves glucose tolerance and enhances insulin secretion in Sprague-Dawley rats[1].
AMG 837 (0.5 mg/kg; p.o.) displays excellent oral bioavailability (F?=?84%) and a total plasma Cmax of 1.4 μM[1]. | Animal Model: | 8-week old Zucker Fatty Rats[1] | | Dosage: | 0.03, 0.1, 0.3 mg/kg | | Administration: | Oral gavage once daily for 21 days | | Result: | Decreased glucose AUC values during the glucose tolerance test (GTT) to 7%, 15%, and 25% at 0.03, 0.1 and 0.3 mg/kg, respectively.
Increased insulin levels in the mid- and high-dose groups.
Not affected body weights during the 21-day treatment. |
| Animal Model: | 8-week old Sprague-Dawley rats[1] | | Dosage: | 0.03, 0.1, 0.3 mg/kg | | Administration: | A single p.o. administration | | Result: | Reduced the post-prandial glucose with the half-maximal dose of 0.05 mg/kg. |
| [storage]
Store at -20°C | [References]
[1] Daniel CHL, et, al. AMG 837: a novel GPR40/FFA1 agonist that enhances insulin secretion and lowers glucose levels in rodents. PLoS One. 2011; 6(11): e27270. DOI:10.1371/journal.pone.0027270
[2] Houze JB, et, al. AMG 837: a potent, orally bioavailable GPR40 agonist. Bioorg Med Chem Lett. 2012 Jan 15; 22(2): 1267-70. DOI:10.1016/j.bmcl.2011.10.118
[3] Daniel CHL, et, al. Identification and pharmacological characterization of multiple allosteric binding sites on the free fatty acid 1 receptor. Mol Pharmacol. 2012 Nov;82(5):843-59. DOI:10.1124/mol.112.079640 |
|
| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Website: |
https://www.bocsci.com |
| Company Name: |
SPIRO PHARMA
|
| Tel: |
|
| Website: |
www.spiropharma.com.cn |
|